-
1
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
10.1056/NEJMoa032691, 15175435
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. 10.1056/NEJMoa032691, 15175435.
-
(2004)
N Engl J Med
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
-
2
-
-
3242686833
-
The price tag on progress--chemotherapy for colorectal cancer
-
10.1056/NEJMp048143, 15269308
-
Schrag D. The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med 2004, 351(4):317-319. 10.1056/NEJMp048143, 15269308.
-
(2004)
N Engl J Med
, vol.351
, Issue.4
, pp. 317-319
-
-
Schrag, D.1
-
3
-
-
33750344252
-
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events
-
Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006, 33(5 Suppl 10):S26-34.
-
(2006)
Semin Oncol
, vol.33
, Issue.5 SUPPL. 10
-
-
Hurwitz, H.1
Saini, S.2
-
4
-
-
33646872630
-
Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants
-
10.1002/cncr.21907, 16639738
-
Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, Bodurka DC. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006, 106(11):2452-2458. 10.1002/cncr.21907, 16639738.
-
(2006)
Cancer
, vol.106
, Issue.11
, pp. 2452-2458
-
-
Elting, L.S.1
Cooksley, C.2
Bekele, B.N.3
Frumovitz, M.4
Avritscher, E.B.5
Sun, C.6
Bodurka, D.C.7
-
5
-
-
56749169353
-
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
-
10.1200/JCO.2008.16.3212, 18854571
-
Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). J Clin Oncol 2008, 26(33):5326-5334. 10.1200/JCO.2008.16.3212, 18854571.
-
(2008)
J Clin Oncol
, vol.26
, Issue.33
, pp. 5326-5334
-
-
Grothey, A.1
Sugrue, M.M.2
Purdie, D.M.3
Dong, W.4
Sargent, D.5
Hedrick, E.6
Kozloff, M.7
-
6
-
-
77956185692
-
Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP)
-
Cohn AL, Bekaii-Saab T, Bendell JC, Hurwitz H, Kozloff M, Roach N, Tezcan H, Feng S, Sing A, Grothey A, et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol (Meeting Abstracts) 2010, 28(15_suppl):3596.
-
(2010)
J Clin Oncol (Meeting Abstracts)
, vol.28
, Issue.15 SUPPL
, pp. 3596
-
-
Cohn, A.L.1
Bekaii-Saab, T.2
Bendell, J.C.3
Hurwitz, H.4
Kozloff, M.5
Roach, N.6
Tezcan, H.7
Feng, S.8
Sing, A.9
Grothey, A.10
-
7
-
-
38349138848
-
Association of insurance with cancer care utilization and outcomes
-
10.3322/CA.2007.0011, 18096863
-
Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008, 58(1):9-31. 10.3322/CA.2007.0011, 18096863.
-
(2008)
CA Cancer J Clin
, vol.58
, Issue.1
, pp. 9-31
-
-
Ward, E.1
Halpern, M.2
Schrag, N.3
Cokkinides, V.4
DeSantis, C.5
Bandi, P.6
Siegel, R.7
Stewart, A.8
Jemal, A.9
-
8
-
-
4143114797
-
Understanding Cancer Treatment and Outcomes: The Cancer Care Outcomes Research and Surveillance Consortium
-
10.1200/JCO.2004.06.020, 15284250
-
Ayanian JZ, Chrischilles EA, Wallace RB, Fletcher RH, Fouad MN, Kiefe CI, Harrington DP, Weeks JC, Kahn KL, Malin JL1, et al. Understanding Cancer Treatment and Outcomes: The Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol 2004, 22(15):2992-2996. 10.1200/JCO.2004.06.020, 15284250.
-
(2004)
J Clin Oncol
, vol.22
, Issue.15
, pp. 2992-2996
-
-
Ayanian, J.Z.1
Chrischilles, E.A.2
Wallace, R.B.3
Fletcher, R.H.4
Fouad, M.N.5
Kiefe, C.I.6
Harrington, D.P.7
Weeks, J.C.8
Kahn, K.L.9
Malin, J.L.1.10
-
9
-
-
80052838065
-
Representativeness of the CanCORS participants relative to Surveillance, Epidemiology & End Results (SEER) Cancer Registries, AcademyHealth Annual Research Meeting
-
Representativeness of the CanCORS participants relative to Surveillance, Epidemiology & End Results (SEER) Cancer Registries, AcademyHealth Annual Research Meeting. , http://bcb.dfci.harvard.edu/catalano/representativenessAHabstrac15jan08.pdf
-
-
-
-
10
-
-
76749139644
-
Fast Stats: An interactive tool for access to SEER cancer statistics
-
Fast Stats: An interactive tool for access to SEER cancer statistics. , http://seer.cancer.gov/statfacts/html/colorect.html
-
-
-
-
11
-
-
2442696436
-
Prognostic importance of comorbidity in a hospital-based cancer registry
-
10.1001/jama.291.20.2441, 15161894
-
Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291(20):2441-2447. 10.1001/jama.291.20.2441, 15161894.
-
(2004)
JAMA
, vol.291
, Issue.20
, pp. 2441-2447
-
-
Piccirillo, J.F.1
Tierney, R.M.2
Costas, I.3
Grove, L.4
Spitznagel, E.L.5
-
12
-
-
33745974294
-
Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey
-
Malin J, Ko C, Ayanian J, Harrington D, Nerenz D, Kahn K, Ganther-Urmie J, Catalano P, Zaslavsky A, Wallace R, et al. Understanding cancer patients' experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Supp Care Cancer 2006, 14(8):837-848.
-
(2006)
Supp Care Cancer
, vol.14
, Issue.8
, pp. 837-848
-
-
Malin, J.1
Ko, C.2
Ayanian, J.3
Harrington, D.4
Nerenz, D.5
Kahn, K.6
Ganther-Urmie, J.7
Catalano, P.8
Zaslavsky, A.9
Wallace, R.10
-
13
-
-
33750302638
-
Bevacizumab prescribing information
-
Bevacizumab prescribing information. , http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf
-
-
-
-
14
-
-
0023790239
-
A note on graphical presentation of estimated odds ratios from several clinical trials
-
10.1002/sim.4780070807, 3413368
-
Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988, 7(8):889-894. 10.1002/sim.4780070807, 3413368.
-
(1988)
Stat Med
, vol.7
, Issue.8
, pp. 889-894
-
-
Galbraith, R.F.1
-
15
-
-
51349135348
-
Imputation in a multiformat and multiwave survey of cancer care
-
He Y, Zaslavsky AM, Harrington DP, Catalano PJ, Landrum MB. Imputation in a multiformat and multiwave survey of cancer care. Proc Joint Stat Meetings Am Stat Assoc 2007, 1541-1549.
-
(2007)
Proc Joint Stat Meetings Am Stat Assoc
, pp. 1541-1549
-
-
He, Y.1
Zaslavsky, A.M.2
Harrington, D.P.3
Catalano, P.J.4
Landrum, M.B.5
-
16
-
-
85101444608
-
Statistical Analysis with Missing Data
-
Hoboken, NJ: Wiley-Interscience, 2
-
Little RJ, Rubin DB. Statistical Analysis with Missing Data. 2002, Hoboken, NJ: Wiley-Interscience, 2.
-
(2002)
-
-
Little, R.J.1
Rubin, D.B.2
-
17
-
-
10444240331
-
Bevacizumab
-
10.1038/nrd1601, 15645606
-
Muhsin M, Graham J, Kirkpatrick P. Bevacizumab. Nat Rev Drug Discov 2004, 3(12):995-996. 10.1038/nrd1601, 15645606.
-
(2004)
Nat Rev Drug Discov
, vol.3
, Issue.12
, pp. 995-996
-
-
Muhsin, M.1
Graham, J.2
Kirkpatrick, P.3
-
18
-
-
80052854928
-
Good News About Cancer. Seriously
-
Good News About Cancer. Seriously. , http://www.businessweek.com/technology/content/jun2004/tc2004063_2435_tc024.htm
-
-
-
-
19
-
-
1242285664
-
Biotechnology: identifying advances from the hype
-
10.1038/nrd1309, 15040581
-
Glassman RH, Sun AY. Biotechnology: identifying advances from the hype. Nat Rev Drug Discov 2004, 3(2):177-183. 10.1038/nrd1309, 15040581.
-
(2004)
Nat Rev Drug Discov
, vol.3
, Issue.2
, pp. 177-183
-
-
Glassman, R.H.1
Sun, A.Y.2
-
20
-
-
77949519818
-
Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer
-
10.1001/jama.2010.272, 2893553, 20233821
-
Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, et al. Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer. JAMA 2010, 303(11):1037-1045. 10.1001/jama.2010.272, 2893553, 20233821.
-
(2010)
JAMA
, vol.303
, Issue.11
, pp. 1037-1045
-
-
Kahn, K.L.1
Adams, J.L.2
Weeks, J.C.3
Chrischilles, E.A.4
Schrag, D.5
Ayanian, J.Z.6
Kiefe, C.I.7
Ganz, P.A.8
Bhoopalam, N.9
Potosky, A.L.10
-
21
-
-
0035804647
-
Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer
-
10.1093/jnci/93.7.501, 11287444
-
Hodgson DC, Fuchs CS, Ayanian JZ. Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer. J Natl Cancer Inst 2001, 93(7):501-515. 10.1093/jnci/93.7.501, 11287444.
-
(2001)
J Natl Cancer Inst
, vol.93
, Issue.7
, pp. 501-515
-
-
Hodgson, D.C.1
Fuchs, C.S.2
Ayanian, J.Z.3
-
22
-
-
0038175326
-
Use of Adjuvant Chemotherapy and Radiation Therapy for Colorectal Cancer in a Population-Based Cohort
-
10.1200/JCO.2003.06.178, 12663717
-
Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, O'Connor LC, West DW, Allen ME, Wolf RE, et al. Use of Adjuvant Chemotherapy and Radiation Therapy for Colorectal Cancer in a Population-Based Cohort. J Clin Oncol 2003, 21(7):1293-1300. 10.1200/JCO.2003.06.178, 12663717.
-
(2003)
J Clin Oncol
, vol.21
, Issue.7
, pp. 1293-1300
-
-
Ayanian, J.Z.1
Zaslavsky, A.M.2
Fuchs, C.S.3
Guadagnoli, E.4
Creech, C.M.5
Cress, R.D.6
O'Connor, L.C.7
West, D.W.8
Allen, M.E.9
Wolf, R.E.10
-
23
-
-
70449380364
-
Atherosclerosis profile and incidence of cardiovascular events: a population-based survey
-
Group tSS
-
Robinson J, Fox K, Bullano M, Grandy S, . Group tSS Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. BMC Cardiovasc Dis 2009, 9(1):46. Group tSS.
-
(2009)
BMC Cardiovasc Dis
, vol.9
, Issue.1
, pp. 46
-
-
Robinson, J.1
Fox, K.2
Bullano, M.3
Grandy, S.4
-
24
-
-
75349099088
-
Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
-
10.1016/j.amjcard.2009.10.014, 20152237
-
Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, et al. Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010, 105(4):445-452. 10.1016/j.amjcard.2009.10.014, 20152237.
-
(2010)
Am J Cardiol
, vol.105
, Issue.4
, pp. 445-452
-
-
Cannon, C.P.1
Rhee, K.E.2
Califf, R.M.3
Boden, W.E.4
Hirsch, A.T.5
Alberts, M.J.6
Cable, G.7
Shao, M.8
Ohman, E.M.9
Steg, P.G.10
-
25
-
-
0035849938
-
Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer
-
Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer. N Engl J Med 2001, 345(2):144-146.
-
(2001)
N Engl J Med
, vol.345
, Issue.2
, pp. 144-146
-
-
Sargent, D.J.1
Niedzwiecki, D.2
O'Connell, M.J.3
Schilsky, R.L.4
-
26
-
-
0035884212
-
Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel
-
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel. J Clin Oncol 2001, 19(18):3801-3807.
-
(2001)
J Clin Oncol
, vol.19
, Issue.18
, pp. 3801-3807
-
-
Rothenberg, M.L.1
Meropol, N.J.2
Poplin, E.A.3
Van Cutsem, E.4
Wadler, S.5
-
27
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
-
10.1200/JCO.2007.14.9930, 18421054
-
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019. 10.1200/JCO.2007.14.9930, 18421054.
-
(2008)
J Clin Oncol
, vol.26
, Issue.12
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
Scheithauer, W.4
Figer, A.5
Wong, R.6
Koski, S.7
Lichinitser, M.8
Yang, T.S.9
Rivera, F.10
-
28
-
-
33750218663
-
Population-Based Assessment of the Surgical Management of Locally Advanced Colorectal Cancer
-
10.1093/jnci/djj396, 17047196
-
Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CHL. Population-Based Assessment of the Surgical Management of Locally Advanced Colorectal Cancer. J Natl Cancer Inst 2006, 98(20):1474-1481. 10.1093/jnci/djj396, 17047196.
-
(2006)
J Natl Cancer Inst
, vol.98
, Issue.20
, pp. 1474-1481
-
-
Govindarajan, A.1
Coburn, N.G.2
Kiss, A.3
Rabeneck, L.4
Smith, A.J.5
Law, C.H.L.6
-
29
-
-
32944478347
-
Geographic and Socioeconomic Variation in the Treatment of Prostate Cancer
-
10.1200/JCO.2005.08.755, 16204005
-
Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and Socioeconomic Variation in the Treatment of Prostate Cancer. J Clin Oncol 2005, 23(31):7881-7888. 10.1200/JCO.2005.08.755, 16204005.
-
(2005)
J Clin Oncol
, vol.23
, Issue.31
, pp. 7881-7888
-
-
Krupski, T.L.1
Kwan, L.2
Afifi, A.A.3
Litwin, M.S.4
-
30
-
-
0026538046
-
Geographic variation in the use of breast-conserving treatment for breast cancer
-
10.1056/NEJM199204233261702, 1552911
-
Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 1992, 326(17):1102-1107. 10.1056/NEJM199204233261702, 1552911.
-
(1992)
N Engl J Med
, vol.326
, Issue.17
, pp. 1102-1107
-
-
Nattinger, A.B.1
Gottlieb, M.S.2
Veum, J.3
Yahnke, D.4
Goodwin, J.S.5
-
31
-
-
33751026369
-
Variation in Chemotherapy Utilization in Ovarian Cancer: The Relative Contribution of Geography
-
Polsky D, Armstrong KA, Randall TC, Ross RN, Even-Shoshan O, Rosenbaum PR, Silber JH. Variation in Chemotherapy Utilization in Ovarian Cancer: The Relative Contribution of Geography. Health Services Res 2006, 41(6):2201-2218.
-
(2006)
Health Services Res
, vol.41
, Issue.6
, pp. 2201-2218
-
-
Polsky, D.1
Armstrong, K.A.2
Randall, T.C.3
Ross, R.N.4
Even-Shoshan, O.5
Rosenbaum, P.R.6
Silber, J.H.7
-
32
-
-
70349434695
-
Breast-Conserving Surgery in Older Patients with Invasive Breast Cancer: Current Patterns of Treatment Across the United States
-
e422, 10.1016/j.jamcollsurg.2009.06.363, 19801315
-
Smith GL, Xu Y, Shih Y-CT, Giordano SH, Smith BD, Hunt KK, Strom EA, Perkins GH, Hortobagyi GN, Buchholz TA. Breast-Conserving Surgery in Older Patients with Invasive Breast Cancer: Current Patterns of Treatment Across the United States. J Am Coll Surg 2009, 209(4):425-433. e422, 10.1016/j.jamcollsurg.2009.06.363, 19801315.
-
(2009)
J Am Coll Surg
, vol.209
, Issue.4
, pp. 425-433
-
-
Smith, G.L.1
Xu, Y.2
Shih, Y.-.C.T.3
Giordano, S.H.4
Smith, B.D.5
Hunt, K.K.6
Strom, E.A.7
Perkins, G.H.8
Hortobagyi, G.N.9
Buchholz, T.A.10
-
33
-
-
78349269095
-
Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population
-
10.1002/cncr.25242, 20578182
-
Fairfield KM, Lucas FL, Earle CC, Small L, Trimble EL, Warren JL. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the medicare population. Cancer 2010, 116(20):4840-4848. 10.1002/cncr.25242, 20578182.
-
(2010)
Cancer
, vol.116
, Issue.20
, pp. 4840-4848
-
-
Fairfield, K.M.1
Lucas, F.L.2
Earle, C.C.3
Small, L.4
Trimble, E.L.5
Warren, J.L.6
-
34
-
-
77954707651
-
Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?
-
10.1200/JCO.2009.26.2758, 20498408
-
Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?. J Clin Oncol 2010, 28(20):3234-3238. 10.1200/JCO.2009.26.2758, 20498408.
-
(2010)
J Clin Oncol
, vol.28
, Issue.20
, pp. 3234-3238
-
-
Mason, A.1
Drummond, M.2
Ramsey, S.3
Campbell, J.4
Raisch, D.5
|